Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $684,334,700 | $699,939,987 | $741,658,095 | $692,899,336 |
| - Cash | $9,791,900 | $3,375,900 | $3,093,300 | $3,268,400 |
| + Debt | $42,506,600 | $39,903,800 | $38,515,900 | $33,644,200 |
| Enterprise Value | $717,049,400 | $736,467,887 | $777,080,695 | $723,275,136 |
| Revenue | $17,600,800 | $15,557,700 | $12,728,500 | $13,532,800 |
| % Growth | 13.1% | 22.2% | -5.9% | – |
| Gross Profit | $14,592,500 | $13,109,900 | $10,504,300 | $11,129,000 |
| % Margin | 82.9% | 84.3% | 82.5% | 82.2% |
| EBITDA | $7,882,000 | $7,503,900 | $4,162,600 | $5,748,200 |
| % Margin | 44.8% | 48.2% | 32.7% | 42.5% |
| Net Income | $5,582,500 | $5,660,500 | $2,759,300 | $4,409,800 |
| % Margin | 31.7% | 36.4% | 21.7% | 32.6% |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 |
| % Growth | -1.3% | 105.6% | -37.3% | – |
| Operating Cash Flow | $8,835,900 | $3,086,900 | $1,665,600 | $2,473,800 |
| Capital Expenditures | -$223,900 | -$1,803,900 | -$3,266,500 | -$1,747,200 |
| Free Cash Flow | $8,612,000 | $1,283,000 | -$1,600,900 | $726,600 |